-+ 0.00%
-+ 0.00%
-+ 0.00%

Adial Pharmaceuticals Publishes International Patent Application For AD04 Serotonin-3 Receptor Antagonist Therapeutic Agent To Treat Alcohol Use Disorder

Benzinga·01/14/2026 14:03:11
Listen to the news

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the publication of the international patent application for AD04, filed in July 2024. AD04 is the Company's lead investigational genetically targeted serotonin-3 receptor antagonist therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients (defined as < 10 drinks/drinking day). The patent, once granted, is expected to protect Adial's core assets through at least 2045.